Albig Allan R, Roy Thessa G, Becenti Darryl J, Schiemann William P
Department of Pharmacology, University of Colorado Health Sciences Center, RC1 South Tower, Room L18-6110, 12801 East 17th Avenue, P.O. Box 6511, Aurora, CO 80045, USA.
Angiogenesis. 2007;10(3):197-216. doi: 10.1007/s10456-007-9075-z. Epub 2007 Jul 14.
Remodeling of vascular microenvironments during normal and tumor-induced angiogenesis is an important, yet poorly understood mechanism by which endothelial cells (ECs) contribute to the activation or resolution of angiogenesis. We used microarray analyses to monitor changes in the transcriptome of ECs undergoing angiogenesis when cultured onto Matrigel matrices. This strategy identified 308 genes whose expression in ECs was altered at least 3-fold by angiogenesis, of which 63 genes were found to encode for secretory proteins. In vitro assays that modeled key steps in the angiogenic process showed that several identified genes possessed pro- or anti-angiogenic activities (e.g., SMOC-2, secreted modular calcium-binding protein-2; CRELD-2, cysteine-rich with EGF-like domains-1; MAGP-2, microfibril-associated glycoprotein-2; lumican; and ECM-1, extracellular matrix protein-1). In particular, MAGP-2 expression potentiated EC proliferation and p38 MAPK activation stimulated by the pro-angiogenic factors, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF); it also stimulated EC invasion and angiogenic sprouting, and more importantly, promoted the development and infiltration of vessels into Matrigel plugs implanted into genetically normal mice. Conversely, lumican inhibited EC activation of p38 MAPK, as well as their invasion, angiogenic sprouting, and vessel formation in mice. Collectively, our findings provide new insights into how EC stromal remodeling regulates angiogenesis activation and resolution, as well as identify two novel EC-secreted stromal proteins that modulate angiogenesis both in vitro and in vivo.
在正常和肿瘤诱导的血管生成过程中,血管微环境的重塑是一种重要但尚未被充分理解的机制,内皮细胞(ECs)通过该机制促进血管生成的激活或消退。我们使用微阵列分析来监测培养在基质胶基质上经历血管生成的内皮细胞转录组的变化。该策略鉴定出308个基因,其在内皮细胞中的表达因血管生成而改变至少3倍,其中63个基因被发现编码分泌蛋白。模拟血管生成过程关键步骤的体外试验表明,几个鉴定出的基因具有促血管生成或抗血管生成活性(例如,SMOC-2,分泌型模块化钙结合蛋白-2;CRELD-2,富含半胱氨酸的表皮生长因子样结构域-1;MAGP-2,微原纤维相关糖蛋白-2;纤连蛋白;以及ECM-1,细胞外基质蛋白-1)。特别是,MAGP-2的表达增强了促血管生成因子碱性成纤维细胞生长因子(bFGF)、表皮生长因子(EGF)和血管内皮生长因子(VEGF)刺激的内皮细胞增殖和p38丝裂原活化蛋白激酶(MAPK)激活;它还刺激内皮细胞侵袭和血管生成芽生,更重要的是,促进血管在植入基因正常小鼠的基质胶栓中的发育和浸润。相反,纤连蛋白抑制内皮细胞中p38 MAPK的激活,以及它们在小鼠体内的侵袭、血管生成芽生和血管形成。总的来说,我们的研究结果为内皮细胞基质重塑如何调节血管生成的激活和消退提供了新的见解,同时也鉴定出两种新的内皮细胞分泌的基质蛋白,它们在体外和体内均能调节血管生成。